BioSpace Insights
The BioSpace Insights team performs research and analysis on industry trends for BioSpace and clients, producing industry reports, podcasts, events and articles.
Latest from Insights
At the GenScript Biotech Global Forum 2025, industry leaders celebrated CAR T cell therapy achievements while discussing ongoing challenges in manufacturing, distribution, treatment center capacity, and global payment structures for cell and gene therapies.
Shaping the Future of Drug Development
LIVE WEBINAR | APRIL 23 | 1PM–2PM EST
In this discussion, our guests explore how recent regulatory changes are shaping the future of AI in drug development in the US market. We will also discuss the ripple effect these changes are having on a global scale. Our guests will provide their insights from investor, regulatory and legal perspectives to unpack the latest changes to guidance and communications their impacts on market and development strategies, cross-border collaboration, and legal frameworks.
LIVE WEBINAR | APRIL 23 | 1PM–2PM EST
In this discussion, our guests explore how recent regulatory changes are shaping the future of AI in drug development in the US market. We will also discuss the ripple effect these changes are having on a global scale. Our guests will provide their insights from investor, regulatory and legal perspectives to unpack the latest changes to guidance and communications their impacts on market and development strategies, cross-border collaboration, and legal frameworks.
Listen to Denatured
Unravel the business of science with BioSpace.
Lori and guests address clinical trial design, which if done without careful consideration of the patient population can exclude patients from clinical trials instead of being inclusive.
In this episode, Lori and guests discuss the pursuit of adequate representation and how clinical trials are being shaped by the legal environment they operate within.
This is the third episode of Denatured’s discussion on diversity, equity and inclusion. Here, our guests discuss imperatives around access and accountability.
Webinars
This webinar explores the pivotal role of patent data in overcoming the data challenges faced by generative AI models in drug discovery, particularly for biologics. Watch now.
BioSpace at 2025 SCOPE Summit
Events
In this live panel discussion, speakers focused on the EU AI Act’s global regulatory implications for medical devices & QARA’s future. An executive summary is available.
- BIO International Convention: June 16-19, 2025 | Boston, MA
- Bioprocessing Summit: August 18-21, 2025 | Boston, MA
- Meeting on the Mesa: October 6-8, 2025 | Phoenix, AZ
BioSpace x DIA
The groundwork being done in 2024 is building the foundation for global collaboration in the future.
DRUG DEVELOPMENT
DRUG DEVELOPMENT
FROM BIOSPACE INSIGHTS
How can startup leaders support long-term sustainable growth and investment? BioSpace’s Lori Ellis speaks with venture capital guests Ansbert Gadicke, Martin Gershon and Mike Goguen for their advice and recommendations on how biopharma startups should approach funding.
What needs to happen for funding in biopharma to bounce back? BioSpace’s Lori Ellis discusses the macroeconomic environment and biopharma funding outlook with venture capital guests Ansbert Gadicke, Martin Gershon and Mike Goguen.
This week, we discuss the two major FDA approvals for sickle cell from Vertex/CRISPR and bluebird bio; Axcella and the future of long-covid treatments, Vanda’s $100m purchase and AI regulatory developments in Europe.
BioSpace and guests from Halia Therapeutics, Triumvira Immunologics and the Alzheimer’s Drug Discovery Foundation will discuss alternative financing strategies to consider for 2024. Watch now.
In this episode we dive into regulation, real-time management, and AI’s various applications and how it can streamline different processes with guests from Microsoft and IQVIA.
In this episode, hear from senior leaders at Microsoft and IQVIA to get their take on how generative AI is impacting productivity, employee engagement and how to mitigate risks.
In this third episode of Denatured’s series on AI in drug discovery, we discuss patient behavior and its influence on clinical trials and AI models with guests from GSK, IQVIA, Exelixis and DataHow.
Listen to this in-depth discussion on how AI can help identify end-to-end data weaknesses, as well as broader implications regarding the inevitability of human interaction, with guests from GSK, IQVIA, Exelixis and DataHow.
This week on The Weekly we talk struggles with GLP-1 drug shortages and what that might mean for Novo and Lilly competitors; Regeneron and Sanofi positive results for Dupixent in COPD. Plus, Merck buys Caraway, Beigene’s deal with Ensem, ups and downs for Flagship.
Advancements in asthma biologics spell future hope for patients with severe asthma.